Highlights and Quick Summary
- Net Debt/EBITDA for the quarter ending September 30, 2022 was -16.5 (a 169.12% increase compared to previous quarter)
- Year-over-year quarterly Net Debt/EBITDA increased by 943.66%
- Annual Net Debt/EBITDA for 2021 was -0.47 (a -440.48% decrease from previous year)
- Annual Net Debt/EBITDA for 2020 was 0.14 (a -83.96% decrease from previous year)
- Annual Net Debt/EBITDA for 2019 was 0.85 (a -4.3% decrease from previous year)
Visit stockrow.com/BCRX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical Net Debt/EBITDA of BioCryst Pharmaceuticals, Inc.Most recent Net Debt/EBITDAof BCRX including historical data for past 10 years.
Interactive Chart of Net Debt/EBITDA of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Net Debt/EBITDA for the past 10 Years (both Annual and Quarterly)
Business Profile of BioCryst Pharmaceuticals, Inc.